ICAHN School of Medicine At Mount Sinai

Christine E. Seidman, MD, awarded 2024 Maria I. New International Prize for Biomedical Research for pioneering cardiovascular genetics, transforming understanding of congenital heart disease and heart muscle disorders. Seidman receives $20,000 and will present a lecture at Icahn Mount Sinai on Nov 8.

NAM elected 90 regular and 10 international members, recognizing outstanding achievements in health and medicine. New members include Carlos L. Arteaga, Nina Bhardwaj, Bob S. Carter, Stephen Jacob Chanock, George Coukos, Lisa M. Coussens, Silvia C. Formenti, Joseph Heitman, Nola M. Hylton, Reshma Jagsi, Peter Anthony Jones, Funda Meric-Bernstam, Deborah Schrag, and Mitchell J. Weiss. Victor J. Dzau, NAM President, highlighted their contributions to health equity and public health challenges.

Intellia Therapeutics reports positive Phase 2 data for NTLA-2002, showing deep attack rate reductions and potential for a functional cure for hereditary angioedema (HAE). Eight of 11 patients in the 50 mg arm were completely attack-free post-infusion. Data published in The New England Journal of Medicine and to be presented at the 2024 ACAAI Scientific Meeting. Intellia is actively screening patients for the global pivotal Phase 3 HAELO study.

Researchers at Icahn School of Medicine may have identified a universally recognized normal value for the fibrinogen and albumin ratio (FAR) in preeclampsia risk assessment.

WNTinib, a kinase inhibitor, delays tumor growth and improves survival in hepatoblastoma, a rare liver cancer in children, targeting the CTNNB1 mutation. Preclinical models show significant tumor reduction and extended survival, suggesting a promising treatment strategy for pediatric patients.

WNTinib, a drug targeting the CTNNB1 mutation in hepatoblastoma, significantly delays tumor growth and improves survival in mice models, suggesting a promising treatment strategy for children with this liver cancer.

RPI awarded two NIA grants for AD research training: $1.2M for T32 program integrating data science, engineering, and life sciences, and $1.26M for RAFAELs program focusing on commercialization. Both programs aim to bridge theory and practice, fostering interdisciplinary research and industry exposure.

A blood test can identify women in labor at risk for preeclampsia by analyzing fibrinogen and albumin levels, with a higher fibrinogen-to-albumin ratio (FAR) indicating increased risk. FAR of 0.1 correlates with a 24% risk, while FAR above 0.3 indicates over 41% risk. This method could aid in early identification and preventive measures.

ARC-SV algorithm identifies complex structural variants near GWAS locations linked to schizophrenia and bipolar disorder, affecting gene expression and suggesting their role in disease development.

The Icahn School of Medicine at Mount Sinai received a $5 million gift from the John and Daria Barry Foundation for the Center for Ophthalmic Artificial Intelligence (AI) and Human Health, now named The Barry Family Center. The funds will support clinical programs, research, and the establishment of an ophthalmic AI fellowship, aiming to enhance early diagnosis of eye diseases and systemic health conditions linked to eye disorders.